Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials [PDF]
, 2016 Objective Previous studies have suggested that niacin treatment raises glucose levels in patients with diabetes and may increase the risk of developing diabetes.
Goldie, Christina +5 more
core +1 more source
Kidney Research and Clinical Practice, 2012 Niacin supplementation improves dyslipidemia and lowers serum phosphorus levels in chronic kidney disease (CKD) patients. However, its adverse effects, including hot flusing, hinder the administration of niacin.
Won Suk An, Hyo Jin Kang, Ki Hyun Kim
doaj +1 more source
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. [PDF]
, 2017 Treatment of dyslipidemia patients with lipid-lowering drugs leads to a significant reduction in low-density lipoproteins (LDL) level and a low to moderate level of increase in high-density lipoprotein (HDL) cholesterol in plasma.
Alderete, Benjamin +7 more
core +1 more source
Glycaemic effects of non-statin lipid-lowering therapies [PDF]
, 2016 Since the publication of the JUPITER trial, attention has been focused on the adverse glycemic effects of statin therapy. Although the modest increase in the risk of new diabetes mellitus is outweighed by the reduction in cardiovascular events for ...
Collins, Patrick D., Sattar, Naveed
core +1 more source
Ezetimibe therapy: mechanism of action and clinical update. [PDF]
, 2012 The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events.
Dayspring, Thomas D +2 more
core +1 more source
Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial. [PDF]
, 2017 Extended-release niacin (ERN) is the most effective agent for increasing high-density lipoprotein-cholesterol (HDL-C). Having previously identified anti-HDL antibodies, we investigated whether ERN affected the antioxidant capacity of HDL and whether ERN ...
Alves, JD +6 more
core +1 more source
Journal of Lipid Research, 2012 The lipidation of apoA-I in liver greatly influences HDL biogenesis and plasma HDL levels by stabilizing the secreted apoA-I. Niacin is the most effective lipid-regulating agent clinically available to raise HDL.
Lin-Hua Zhang +4 more
doaj +1 more source
Influence of niacin supplementation on the metabolic parameters and lipolysis in dairy cows during early lactation [PDF]
Kafkas Universitesi Veteriner Fakültesi Dergisi, 2017 The objective of this study was to evaluate the effect of niacin on the metabolic parameters and lipolysis inhibition in dairy cows during early lactation.
Talija HRISTOVSKA +5 more
doaj +1 more source
Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]
, 2017 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah +13 more
core +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source